
Bruker (BRKR) Stock Forecast & Price Target
Bruker (BRKR) Analyst Ratings
Bulls say
Bruker Corporation is expected to have an adjusted EPS increase of 11-13%, indicating strong financial performance and a favorable outlook for profitability. The company reported organic revenue growth of 4.5%, significantly surpassing market consensus, while also achieving a 3.9% growth in overall revenues, highlighting robust demand across its segments. Additionally, improvements in adjusted gross margins, coupled with a solid backlog and growth drivers such as semi-metrology, further position Bruker favorably in the scientific instruments and diagnostics market.
Bears say
Bruker Corporation has faced a decline in organic revenue within its Supercon Technologies (BEST) segment, posting a 2.8% decrease and raising concerns regarding its growth prospects in a challenging market environment. The potential for reduced funding from the NIH, projected to decrease by 8-10% and contribute nearly $15 million in lost revenue, coupled with uncertainties surrounding competition and demand in key regions, particularly Europe, indicates heightened risks to future earnings. Furthermore, ongoing legal challenges regarding the GeoMx injunction may adversely impact instrument sales and create additional headwinds for the company through fiscal year 2025.
This aggregate rating is based on analysts' research of Bruker and is not a guaranteed prediction by Public.com or investment advice.
Bruker (BRKR) Analyst Forecast & Price Prediction
Start investing in Bruker (BRKR)
Order type
Buy in
Order amount
Est. shares
0 shares